Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.

AS, Hss; MT, Koh; KK, Tan; LG, Chan; L, Zhou; A, Bouckenooghe; D, Crevat; Y, Hutagalung

doi:10.1016/j.vaccine.2013.10.013

Public

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.

Shared by NobleBlocks on Oct 14, 2013 • 12:00 AM UTC

Authors:

Hss AS

Koh MT

Tan KK

Abstract

<h4>Background</h4>Dengue disease is a major public health problem across the Asia-Pacific region for which there is no licensed vaccine or treatment. We evaluated the safety and immunogenicity of Phase III lots of a candidate vaccine (CYD-TDV) in children in Malaysia.<h4>Methods</h4>In this observe...

Subject

Safety

Vaccine

Immunogenicity

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!